利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

53 条记录 (耗时 0.056 秒)

    USE OF A PEPTIDE AS A THERAPEUTIC AGENT
    7.
    发明申请
    USE OF A PEPTIDE AS A THERAPEUTIC AGENT 审中-公开
    使用作为治疗剂的肽

    公开(公告)号：US20100197587A1

    公开(公告)日：2010-08-05

    申请号：US12677266

    申请日：2008-09-09

    申请人： Dorian Bevec ,  Fabio Cavalli ,  Vera Cavalli ,  Gerald Bacher

    发明人： Dorian Bevec ,  Fabio Cavalli ,  Vera Cavalli ,  Gerald Bacher

    IPC分类号： A61K38/17 ,  A61P3/00 ,  A61P9/00 ,  A61P11/00 ,  A61P25/28 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00

    CPC分类号： A61K38/23 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393 ,  Y02A50/397 ,  Y02A50/402 ,  Y02A50/406 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/422 ,  Y02A50/423 ,  Y02A50/469 ,  Y02A50/49

    摘要： The present invention is directed to the use of the peptide compound His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-Arg-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

    摘要翻译： 本发明涉及肽化合物His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala- Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-Arg-OH作为预防和/或治疗癌症，自身免疫性疾病，纤维化疾病 炎性疾病，神经变性疾病，传染病，肺部疾病，心脏和血管疾病以及代谢疾病。 此外，本发明涉及优选形式为冻干物或液体缓冲溶液或人造母乳制剂或含有肽His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met- Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-Arg-OH 以及至少一种药学上可接受的载体，冷冻保护剂，冻干保护剂，赋形剂和/或稀释剂。

    USE OF THE HUMAN PANCREATIC POLYPEPTIDE AS A THERAPEUTIC AGENT
    8.
    发明申请
    USE OF THE HUMAN PANCREATIC POLYPEPTIDE AS A THERAPEUTIC AGENT 审中-公开
    使用人胰腺多肽作为治疗药物

    公开(公告)号：US20100184677A1

    公开(公告)日：2010-07-22

    申请号：US12677743

    申请日：2008-09-09

    申请人： Dorian Bevec ,  Fabio Cavalli ,  Vera Cavalli ,  Gerald Bacher

    发明人： Dorian Bevec ,  Fabio Cavalli ,  Vera Cavalli ,  Gerald Bacher

    IPC分类号： A61K38/17 ,  C07K14/435 ,  A61P31/20 ,  A61P3/00 ,  A61P9/00 ,  A61P11/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00 ,  A61P25/28

    CPC分类号： A61K38/09 ,  A61K38/33 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/401 ,  Y02A50/402 ,  Y02A50/406 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/422 ,  Y02A50/423 ,  Y02A50/465 ,  Y02A50/469 ,  Y02A50/471 ,  Y02A50/481 ,  Y02A50/49 ,  A61K2300/00

    摘要： The present invention is directed to the use of the peptide compound Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp- Asn-Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asn- Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

    摘要翻译： 本发明涉及肽化合物Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asn-Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln- Tyr-Ala-Ala-Asp-Leu-Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2作为预防和/或治疗癌症的自身免疫 疾病，纤维化疾病，炎性疾病，神经退行性疾病，感染性疾病，肺部疾病，心血管疾病和代谢疾病。 此外，本发明涉及优选形式为冻干物或液体缓冲溶液或人造母乳制剂或含有Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp- Asn-Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Pro-Arg- Tyr-NH 2任选与至少一种药学上可接受的载体，冷冻保护剂，冻干保护剂，赋形剂和/或稀释剂一起。

    USE OF A GLP-1 MOLECULE FOR TREATMENT OF BILIARY DYSKINESIA AND/OR BILIARY PAIN/DISCOMFORT
    9.
    发明申请
    USE OF A GLP-1 MOLECULE FOR TREATMENT OF BILIARY DYSKINESIA AND/OR BILIARY PAIN/DISCOMFORT 审中-公开
    用于治疗胆汁淤积症和/或胆汁淤积/分泌的GLP-1分子的使用

    公开(公告)号：US20090181887A1

    公开(公告)日：2009-07-16

    申请号：US12066178

    申请日：2006-09-06

    申请人： Christian Hansen ,  Henrik Nilsson ,  Hans T. Schambye ,  Tina Geritz Nielsen

    发明人： Christian Hansen ,  Henrik Nilsson ,  Hans T. Schambye ,  Tina Geritz Nielsen

    IPC分类号： A61K38/22 ,  A61P25/00 ,  G01N33/566

    CPC分类号： A61K38/26 ,  G01N2333/605 ,  G01N2500/02 ,  G01N2800/08 ,  Y02A50/49

    摘要： The present invention relates to molecules, compositions and methods suitable for the treatment or prevention of biliary dyskinesia and/or pain and/or discomfort originating from the biliary tree. The peptide hormone glucagon-like peptide-1 (GLP-1) has both anti-secretory effects and smooth muscle relaxatory properties in the gastrointestinal tract. GLP-1 exists in several forms, where the natural occurring GLP-1 molecules are GLP-1 (1-37), GLP-1 (7-37), and the amidated versions GLP-1 (1-36)amide, GLP-1 (7-36)amide. Other molecules capable of binding to and activating the GLP-1 receptor is herein included in the tern GLP-1 molecules. GLP-1 molecules may be naturally occurring or homologues of GLP-1 having one or more amino acid substitutions or modifications. The GLP-1 molecules are used for the manufacture of a medicament for the treatment or prevention of biliary dyskinesia and/or pain and/or discomfort originating from the biliary tree.

    摘要翻译： 本发明涉及适用于治疗或预防来自胆道树的胆汁运动障碍和/或疼痛和/或不适的分子，组合物和方法。 肽激素胰高血糖素样肽-1（GLP-1）在胃肠道中具有抗分泌作用和平滑肌松弛性质。 GLP-1以几种形式存在，其中天然存在的GLP-1分子是GLP-1（1-37），GLP-1（7-37）和酰胺化型GLP-1（1-36）酰胺，GLP -1（7-36）酰胺。 在GLP-1分子中包括能够结合并激活GLP-1受体的其它分子。 GLP-1分子可以是具有一个或多个氨基酸取代或修饰的GLP-1的天然存在或同源物。 GLP-1分子用于制造用于治疗或预防胆汁运动障碍和/或来自胆道树的疼痛和/或不适的药物。